The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on percutaneous cryotherapy for renal tumours.

This document replaces previous guidance on cryotherapy for renal cancers (NICE interventional procedure guidance 207, January 2007).


Renal cancer occurs in the lining of the very small tubes in the kidney. Cryotherapy uses cold temperatures to destroy cancer cells through the insertion of a surgical instrument that applies freezing temperatures (cryoprobe) into the tumour.

Coding recommendations

M13.8 Other specified percutaneous puncture of kidney

Y13.2 Cryotherapy to lesion of organ NOC

Y53.- Approach to organ under image control

Note: Codes within category Y53.- are used as secondary codes to classify interventions that are percutaneous and require some form of image control: if the method of image control is unspecified, Y53.9 Unspecified approach to organ under image control is assigned.  

In addition ICD-10 codes C64.X Malignant neoplasm of kidney, except renal pelvis, C65.X Malignant neoplasm of renal pelvis orC79.0 Secondary malignant neoplasm of kidney and renal pelvis are assigned for renal malignancies or D30.0 Benign neoplasm of kidney or D30.1 Benign neoplasm of renal pelvis for benign neoplasms of the kidney.

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer. 

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

  • National Institute for Health and Care Excellence (NICE)